Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Golden Meditech Holdings Limited 金衛醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 00801)

APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

Reference is made to the announcements of Golden Meditech Holdings Limited (the "Company") dated 8 May 2015 in relation to, among other things, the proposed major transaction and connected transaction in relation to acquisition of the convertible notes of China Cord Blood Corporation from Magnum Opus International Holdings Limited and dated 6 August 2015 in relation to, among other things, the delay in despatch of circular. Terms defined in the abovesaid announcements shall have the same meanings when used herein unless the context requires otherwise.

The Board is pleased to announce that SPDB International Holdings Limited, a licensed corporation to carry out Type 4 (advising on securities), Type 6 (advising on corporate finance) and Type 9 (asset management) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), has been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders on the Magnum Agreement and the transactions contemplated thereunder. The appointment of SPDB International Holdings Limited has been approved by the Independent Board Committee.

The letter of advice from the Independent Financial Adviser on the Magnum Agreement and the transactions contemplated thereunder will be included in the circular to be despatched to the Shareholders in due course.

By order of the Board

Golden Meditech Holdings Limited

Kam Yuen

Chairman

Hong Kong, 1 September 2015

As at the date of this announcement, the Board comprises 9 Directors. The executive Directors are Mr. Kam Yuen (Chairman), Mr. Kong Kam Yu and Mr. Yu Kwok Kuen, Harry; the non-executive Directors are Ms. Zheng Ting and Mr. Gao Yue; and the independent non-executive Directors are Prof. Cao Gang, Mr. Feng Wen, Prof. Gu Qiao and Mr. Daniel Foa.